Anti-TCF3 Antibody (R3E17)

Catalog No.

RHD13901

Species reactivity

Human

Host species

Mouse

Isotype

IgG1

Clonality

Monoclonal

Tested applications

FCM: 1:200-1:400, WB: 1:500-1:2000

Target

Immunoglobulin transcription factor 1, Kappa-E2-binding factor, TCF3, Transcription factor ITF-1, Immunoglobulin enhancer-binding factor E12/E47, E2A, bHLHb21, TCF-3, Transcription factor E2-alpha, Transcription factor 3, Class B basic helix-loop-helix protein 21, ITF1, BHLHB21

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P15923

Applications

FCM, WB

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4, 0.05% Sodium Azide.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

R3E17

From agammaglobulinemia to neutropenia: 'The TCF-3 has different clinical presentations'., PMID:39523462

Autosomal dominant TCF3 deficiency with absent B cells and a unique immunoglobulin profile., PMID:39295294

Transcriptional function of E2A, Ebf1, Pax5, Ikaros and Aiolos analyzed by in vivo acute protein degradation in early B cell development., PMID:39179932

B-cells absence in patients diagnosed as inborn errors of immunity: a registry-based study., PMID:38683392

Presence of leukemic clone-specific immunoglobulin heavy chain rearrangements in neonatal blood spots of children with B-cell precursor acute lymphoblastic leukemia., PMID:37929321

Case report: Clinicopathological and molecular characteristics of pediatric-type follicular lymphoma., PMID:37539011

TCF3 haploinsufficiency defined by immune, clinical, gene-dosage, and murine studies., PMID:37277074

Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma., PMID:36631435

Copy Number Alteration and Mutational Profile of High-Grade B-Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements, Diffuse Large B-Cell Lymphoma with MYC-Rearrangement, and Diffuse Large B-Cell Lymphoma with MYC-Cluster Amplification., PMID:36497332

A p38α-BLIMP1 signalling pathway is essential for plasma cell differentiation., PMID:36443297

Expression of TCF3 target genes defines a subclass of diffuse large B-cell lymphoma characterized by up-regulation of MYC target genes and poor clinical outcome following R-CHOP therapy., PMID:36336953

Lineage Conversion in Pediatric B-Cell Precursor Acute Leukemia under Blinatumomab Therapy., PMID:35409391

Resistance Mechanisms in Pediatric B-Cell Acute Lymphoblastic Leukemia., PMID:35328487

NOX4 stimulates ANF secretion via activation of the Sirt1/Nrf2/ATF3/4 axis in hypoxic beating rat atria., PMID:35029280

Primary antibody deficiencies in Turkey: molecular and clinical aspects., PMID:34618307

Comparison of Two Quantitative PCR-Based Assays for Detection of Minimal Residual Disease in B-Precursor Acute Lymphoblastic Leukemia Harboring Three Major Fusion Transcripts., PMID:34325057

Expression of BCL6 in paediatric B-cell acute lymphoblastic leukaemia and association with prognosis., PMID:34049715

TCF3 Dominant Negative Variant Causes an Early Block in B-Lymphopoiesis and Agammaglobulinemia., PMID:33905048

Stimulated by retinoic acid gene 8 (STRA8) interacts with the germ cell specific bHLH factor SOHLH1 and represses c-KIT expression in vitro., PMID:33236849

Rewiring of B cell receptor signaling by Epstein-Barr virus LMP2A., PMID:33020271

Recurrent genetic abnormalities detected by FISH in adult B ALL and association with hematological parameters., PMID:32902203

The Transcription Factor SCX is a Potential Serum Biomarker of Fibrotic Diseases., PMID:32708589

Burkitt lymphoma: bridging the gap between advances in molecular biology and therapy., PMID:32255708

The Incidence and Immunophenotypic and Genetic Features of JL1 Expressing Cells and the Therapeutic Potential of an Anti-JL1 Antibody in De Novo Pediatric Acute Leukemias., PMID:30809981

Durable remissions in TCF3-HLF positive acute lymphoblastic leukemia with blinatumomab and stem cell transplantation., PMID:30765470

Flow cytometric predictive scoring systems for common fusions ETV6/RUNX1, BCR/ABL1, TCF3/PBX1 and rearrangements of the KMT2A gene, proposed for the initial cytogenetic approach in cases of B-acute lymphoblastic leukemia., PMID:30730614

[New molecular pathological strategies for malignant iris tumors]., PMID:30623224

Epigenetic Enhancer Marks and Transcription Factor Binding Influence Vκ Gene Rearrangement in Pre-B Cells and Pro-B Cells., PMID:30271408

Generation of novel Id2 and E2-2, E2A and HEB antibodies reveals novel Id2 binding partners and species-specific expression of E-proteins in NK cells., PMID:30144957

YY1 binds to the E3' enhancer and inhibits the expression of the immunoglobulin κ gene via epigenetic modifications., PMID:30098214

Autosomal Recessive Agammaglobulinemia - first case with a novel TCF3 mutation from Pakistan., PMID:30063982

Clinical Implications of Digenic Inheritance and Epistasis in Primary Immunodeficiency Disorders., PMID:29434582

Epistatic interactions between mutations of TACI (TNFRSF13B) and TCF3 result in a severe primary immunodeficiency disorder and systemic lupus erythematosus., PMID:29114388

Regulated localization of an AID complex with E2A, PAX5 and IRF4 at the Igh locus., PMID:27835756

The Expression Pattern of the Pre-B Cell Receptor Components Correlates with Cellular Stage and Clinical Outcome in Acute Lymphoblastic Leukemia., PMID:27611867

Transcription factor 7-like 1 dysregulates keratinocyte differentiation through upregulating lipocalin 2., PMID:27551519

Dynamic changes in Id3 and E-protein activity orchestrate germinal center and plasma cell development., PMID:27217539

Basic helix loop helix (bHLH) transcription factor 3 (TCF3, E2A) is regulated by androgens in prostate cancer cells., PMID:26807321

The presence of genomic imbalances is associated with poor outcome in patients with burkitt lymphoma treated with dose-intensive chemotherapy including rituximab., PMID:26567765

Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options., PMID:26214592

De novo DNA Methyltransferases Dnmt3a and Dnmt3b regulate the onset of Igκ light chain rearrangement during early B-cell development., PMID:26059604

Analysis of candidate genes for lineage-specific expression changes in humans and primates., PMID:24911366

Targeting the B-cell receptor signaling pathway in B lymphoid malignancies., PMID:24811161

Expression and recruitment of uracil-DNA glycosylase are regulated by E2A during antibody diversification., PMID:24747958

The combined expression of VPREB3 and ID3 represents a new helpful tool for the routine diagnosis of mature aggressive B-cell lymphomas., PMID:24493312

Allelic exclusion of IgH through inhibition of E2A in a VDJ recombination complex., PMID:24470503

miR-24 affects hair follicle morphogenesis targeting Tcf-3., PMID:24232098

A recurrent dominant negative E47 mutation causes agammaglobulinemia and BCR(-) B cells., PMID:24216514

Early B-cell factor 1 regulates the expansion of B-cell progenitors in a dose-dependent manner., PMID:24078629

Parity induces differentiation and reduces Wnt/Notch signaling ratio and proliferation potential of basal stem/progenitor cells isolated from mouse mammary epithelium., PMID:23621987

Document Download

Anti-TCF3 Antibody (R3E17).pdf